Drug Profile
LY 104658
Latest Information Update: 13 Dec 1996
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Anti-ischaemics; Neuroprotectants; Small molecules
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
Most Recent Events
- 13 Dec 1996 No-Development-Reported for Neurological disorders in USA (Unknown route)
- 04 Jan 1995 Preclinical development for Cognition disorders in USA (Unknown route)